366 related articles for article (PubMed ID: 37016189)
1. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
3. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
[TBL] [Abstract][Full Text] [Related]
5. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
[TBL] [Abstract][Full Text] [Related]
7. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
9. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Li P; Wu X; Li Y; Huang J
Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
[TBL] [Abstract][Full Text] [Related]
10. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
11. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
12. Treatment for osteoporosis in people with beta-thalassaemia.
Bhardwaj A; Swe KMM; Sinha NK
Cochrane Database Syst Rev; 2023 May; 5(5):CD010429. PubMed ID: 37159055
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
14. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
15. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
16. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Shen J; Ke Z; Dong S; Lv M; Yuan Y; Song L; Wu K; Xu K; Hu Y
Med Sci Monit; 2022 Apr; 28():e935491. PubMed ID: 35430576
[TBL] [Abstract][Full Text] [Related]
18. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
19. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]